 |
|
|
| |
Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis
|
| |
| |
Reported by Jules Levin
AASLD Annual Meeting 2017, Washington, DC, USA, October 20-24
Li-Juan Jiang1,*, Dipankar Bhattacharya2, Young J. Yoon2, Hsin-I Chou2, Mary Chau1, Yang Li1, Yat Sun Or1, Scott L. Friedman2
1 Enanta Pharmaceuticals, Inc., Watertown, MA, USA; 2 Icahn School of Medicine at Mount Sinai, New York, NY, USA
|
| |
|
|
|
|
|
